Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. - Wikidata - awgldk - TriplyDB

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

http://www.wikidata.org/entity/Q33647411

about

Epigenetic regulators and their impact on therapy in acute myeloid leukemia Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research Myeloid malignancies: mutations, models and management IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations Myeloid neoplasias: what molecular analyses are telling us Clinical effect of point mutations in myelodysplastic syndromes Activating CBL mutations are associated with a distinct MDS/MPN phenotype.Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases.The molecular basis of myeloid malignancies.Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations Downregulated stromal antigen 2 expression in de novo acute myeloid leukemia patients.Regulation of stem cell function by protein ubiquitylation Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Update on cytogenetic and molecular changes in myelodysplastic syndromes.Molecular biology of myelodysplastic syndromes.Mutations in epigenetic regulators in myelodysplastic syndromes.

P2860

Q26765402-59F7EF18-7B10-4B5F-BB91-CCE0F06EEEF3 Q26859843-5280A2BD-9715-4F0C-B6FE-C7F89FBD1959 Q27000577-9AC82E29-1AA2-4000-9650-2331EDCDA2B4 Q27851676-A509D490-DEF3-4286-9D14-6C995E9D0FEB Q27851909-4A934421-291D-406E-816A-CEBD68CEED52 Q27853094-E5355866-2E07-4433-99BA-335B57BBF8E8 Q28255707-B5FE30C0-057E-4B10-A03F-5866197BB4DB Q28590040-9AD51D59-69F8-46B1-AFA6-7223F0EAA377 Q33354547-79B2EFFB-9385-46B9-872F-B2D5DE089F52 Q33395996-A73C83E3-26E5-4CE4-80DE-A03FF7463D5F Q33403530-B6128FF4-9813-4B05-AD66-A1BE22536B20 Q33434835-8307AC45-085C-4DED-BFAB-08F9D7EF4F4C Q33558105-EA3347E7-B61A-4989-B3FA-8D8F7081AFC6 Q33667448-3C30534E-72C1-4FDC-AEC9-BEEC6CE8E957 Q33769072-26EADBA2-3DF1-4657-A86A-27E70B2ABF9E Q34119417-ED4432CE-DEF7-4144-BB15-21E01BE580B1 Q34388734-8BDA7B94-5858-4F96-B83A-FC9B2D8ADAAA Q34661033-1F48B55F-3D73-4B70-B57A-35FE7B9E4B10 Q34684285-7087E482-CBEA-4914-9927-258C2D03F60B Q34748960-BD77DA50-FCD2-48E8-9959-8CBFADA8E794 Q35007645-1492A587-0A53-4A41-91E3-7B517A11DC5A Q35103708-DFE2AFE2-2B16-450F-8ABD-54C93A1EC410 Q35332017-36877A56-BB90-43AC-B6EE-AE162A60BD95 Q35581289-45415DE8-ACE9-4BBA-B3A4-10D2DC5DCCB2 Q35816648-8D3FC529-EBCC-419D-8526-5FB4AF793A98 Q36498395-CEB2415F-5B1C-4672-95C6-70717BE859C8 Q36522731-3EFC19A4-3FD9-41E9-84AA-60ED2282C8B4 Q36848202-A07AA7F1-3C64-43F6-A529-3B581C350A6A Q36936451-06D79CD8-1E44-4E8D-95C7-2A62B8395184 Q36958309-C40DEA38-B50C-4B87-B20A-038F1BE68C83 Q36960990-618F2699-BA0B-4099-8AED-4E42CA3DCF97 Q37555315-22E2A038-9F5A-4CA2-921A-C0D169A9F348 Q37631229-2C5C7F95-47FF-478A-8F91-3324386322CC Q37688148-F95D0FB7-1EF4-4575-A93D-E8D9C3B028AE Q37697637-8FCB0958-B26C-4542-84AA-5693678FD6AB Q37707515-7CD5A1E1-2B4F-4695-B039-F0BD66AB53E0 Q37872296-30BDC10A-7544-41E2-8CA9-7ED20EA3B53B Q37923939-8D1E3A26-A51C-476F-9719-6E71B8F13973 Q37937809-87CCDF64-AACF-49F9-8F0C-14839BF2E3CD Q37974844-B049EEF8-A537-4AA0-8049-EB7B45E174B3

P2860

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

http://www.wikidata.org/entity/Q33647411

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@ast

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@en

type

label

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@ast

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@en

prefLabel

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@ast

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@en

P1433

Q33647411-8CEF6740-F1D4-4CDF-B71B-61BE94DCB2E3

P1476

Q33647411-1499C0D5-22DA-4B4A-B271-A50570215E94

P2093

Q33647411-00637BC8-7CA0-493C-BECB-2765D85565E9

Q33647411-1CE8063F-4A16-4133-8ECD-76F931545A33

Q33647411-5DC5730E-4552-4405-AA79-C002B82A2BB6

Q33647411-6D91B985-45D0-4894-8A6B-5C695A973F9F

Q33647411-A5C4EEAC-0E86-40DC-B6D4-E3BF0C36677D

Q33647411-D1F40C2A-4A4D-4F9A-8755-4A586F37F65B

Q33647411-D240DE56-AB82-46F0-BFAE-71202F437FFA

Q33647411-D5FD8F83-6ABE-4541-9B67-10058DA9FB58

Q33647411-F3553F94-4948-4742-96EC-FE39074AAC3B

Q33647411-F89ECD1D-4FD9-4487-8044-9E08FFDA2F76

P2860

Q33647411-01AF37DA-E357-4263-95C5-BA4D90A3185F

Q33647411-06F3D25C-26D1-413D-A441-DDD68207FB77

Q33647411-09191A61-B804-4B8E-97D1-7B428AE2E9F0

Q33647411-0E25C94C-2355-4BA5-A56E-DF290C1A3CFE

Q33647411-128D2082-83BC-4DBB-B091-17D7E467A8AD

Q33647411-17CCA3EA-34A3-425C-A7A2-F0D883332FFF

Q33647411-1B1EFB6C-4412-4791-B1F9-19438F33EAC7

Q33647411-24D760BD-DF8E-45E8-8648-9DF729EC861D

Q33647411-2710DCC6-54F9-473D-BE2A-93DA44633814

Q33647411-2FF4224E-6855-482D-BA71-8DA7C66FFB77

P2888

Q33647411-6A550ACA-1E65-4FAB-A92E-BC9FF6038A8D

P304

Q33647411-AC588E50-2123-446D-887D-8873A5F94673

P31

Q33647411-CD3E75EC-31E4-44AB-8E9E-1B607D37EF86

P356

Q33647411-428A4624-30D0-4BF5-A0C8-2D5E6D531AF2

P407

Q33647411-2EE8B8DD-EDAE-4DFA-A2CA-5289B1A85CDC

P478

Q33647411-E84AD4C3-7FD3-4751-BC12-926782E70E18

P50

Q33647411-37A58689-86F2-48E0-9587-415B0C70A72A

Q33647411-8687B705-F161-4D3E-B24B-AEF9A5669FFB

Q33647411-A48811EC-6E73-40C3-9639-66E4DE8E1F07

P577

Q33647411-1A64B65E-F610-4B2F-9588-A613C2DC4742

P5875

Q33647411-F5B6FDB3-9211-4300-AF1E-B95B7E436873

P6179

Q33647411-13524869-2CAA-47BA-A2EE-68B0F8535E4D

P698

Q33647411-13C771EF-74D1-469A-BA35-315C8D3D8E57

P932

Q33647411-DA1727F9-0CBD-4005-A8C0-4C503B2BB42A

P356

1471-2407-10-401

P1433

P1476

Combined mutations of ASXL1, C ...... s and acute myeloid leukemias.

@en

P2093

Anne Murati

http://www.w3.org/2001/XMLSchema#string

Daniel Birnbaum

http://www.w3.org/2001/XMLSchema#string

Julien Rocquain

http://www.w3.org/2001/XMLSchema#string

Marie-Joelle Mozziconacci

http://www.w3.org/2001/XMLSchema#string

Meyer Nezri

http://www.w3.org/2001/XMLSchema#string

Nadine Carbuccia

http://www.w3.org/2001/XMLSchema#string

Norbert Vey

http://www.w3.org/2001/XMLSchema#string

Stéphane Raynaud

http://www.w3.org/2001/XMLSchema#string

Sylviane Olschwang

http://www.w3.org/2001/XMLSchema#string

Virginie Trouplin

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Recurring mutations found by sequencing an acute myeloid leukemia genome

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia

P2888

1471-2407-10-401

P304

401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-401

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Joëlle Mozziconacci

Véronique Gelsi-Boyer

Sylviane Olschwang

P577

2010-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45460398

http://www.w3.org/2001/XMLSchema#string

P6179

1015343459

http://www.w3.org/2001/XMLSchema#string

P698

20678218

http://www.w3.org/2001/XMLSchema#string

P932

2923633

http://www.w3.org/2001/XMLSchema#string